Katherine Hu, DO
Endocrinology, Diabetes & Metabolism · Neptune, NJNPI 1356879977
Payments from drug & device makers
Across 337 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$796
- Novo Nordisk$686
- Dexcom, Inc.$516
- Lilly USA, LLC$475
- Sanofi-aventis U.S. LLC$445
- Amgen$407
- plus $3K from 23 others
What the payments were for
- Food & beverage$5,925100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 48 | $796 |
| Novo Nordisk | 49 | $686 |
| Dexcom, Inc. | 20 | $516 |
| Lilly USA, LLC | 32 | $475 |
| Sanofi-aventis U.S. LLC | 23 | $445 |
| Amgen | 24 | $407 |
| Xeris Pharmaceuticals, Inc. | 16 | $299 |
| AbbVie | 18 | $289 |
| Medtronic | 10 | $282 |
| Insulet Corporation | 10 | $217 |
| Embecta Corp. | 13 | $174 |
| Abbott | 5 | $158 |
| Pfizer | 8 | $151 |
| Bayer | 8 | $135 |
| Recordati_rare_diseases_inc. | 6 | $132 |
| Amneal Pharmaceuticals LLC | 8 | $126 |
| Radius Health, Inc. | 6 | $108 |
| Ascendis Pharma Endocrinology Inc | 6 | $103 |
| AstraZeneca(2 entities) | 6 | $92 |
| Boehringer Ingelheim | 5 | $69 |
| Chiesi USA, Inc. | 3 | $53 |
| Almatica Pharma LLC | 3 | $48 |
| Ionis Pharmaceuticals, Inc. | 2 | $36 |
| Tolmar, Inc. | 2 | $33 |
| Mannkind Corporation | 2 | $28 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| UCB, Inc. | 1 | $12 |
How this compares
$5,925 in reported general payments places this provider in the 70th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 193 | $286,752 |
| TrulicityDulaglutide | 99 | $135,451 |
| MounjaroTirzepatide | 88 | $128,736 |
| JardianceEmpagliflozin | 77 | $97,514 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $55,453 |
| FarxigaDapagliflozin Propanediol | 36 | $42,607 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $32,408 |
| TradjentaLinagliptin | 21 | $28,346 |
| JanuviaSitagliptin Phosphate | 17 | $26,945 |
| RybelsusSemaglutide | 12 | $25,246 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $22,332 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $13,933 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $13,166 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $11,426 |
| Novolog FlexpenInsulin Aspart | 32 | $11,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $686 | $311,998205 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $475 | $264,187187 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $69 | $158,268120 claims |
| AstraZenecaFarxiga | $92 | $42,60736 claims |
| AbbVieSynthroid | $289 | $4,42046 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $126 | $3,367216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Neptune
- Danielle LannNeptune$20K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.